glp‑1 drug sourcing
Semaglutide vs Tirzepatide Hidden Supply Clash
Hospitals can maintain GLP-1 therapy by moving to 503A compounding, negotiating direct manufacturer contracts, and partnering with specialty pharmacies while following FDA shipment-control guidance. This approach mitigates the loss of bulk-supply access and keeps patients on weight-loss regimens without interruption. Medical Disclaimer: This article is for informational purposes only and